Safeguard Scientifics®
Fosters Job Growth

Learn more about open positions at our innovative partner companies.

View Opportunities

In 2014,
Crescendo Bioscience
was acquired by
Myriad Genetics (NASDAQ:MYGN)
.

Learn More

In 2014, NuPathe
(Nasdaq:PATH)
was acquired by
Teva Pharmaceutical
Industries Ltd. (NYSE:TEVA)
.

Learn More

In 2014, Alverix was acquired by BD (Becton, Dickinson and Company)
(NYSE: BDX) for $40M, plus
an earn-out of up to $18M,
representing for Safeguard a

1.9x  Cash-on-
  Cash Return

Learn More

In 2013, ThingWorx was acquired
by PTC for $112M, plus an
earn-out of up to $18M,
representing for Safeguard a

4x  Cash-on-
  Cash Return

Learn More

In 2011, on the eve of pricing an IPO, Shire Plc (NASDAQ:SPHGY) acquired Advanced BioHealing for $750M, in cash, representing for Safeguard a

13x  Cash-on-
  Cash Return

Learn More

In 2011, McKesson (NYSE: MCK)
acquired Portico Systems
for $90M, in cash,
representing for Safeguard a

4x  Cash-on-
  Cash Return

Learn More

In 2010, GE Healthcare acquired Clarient, generating the largest net gain in Safeguard’s history. Since
its repositioning, this achieved
for Clarient an increase of

5x  In
  Market Cap

Learn More

In 2010, Eli Lilly acquired Avid Radiopharmaceuticals for $300M, representing for Safeguard a

3x  Cash-on-
  Cash Return

Learn More

not your typical venture capital provider

We’re not your typical capital provider.

From our strategic and operational expertise to our extensive network and resources, Safeguard is committed to building great companies.

Learn More

We partner
with healthcare and technology companies.

What We Look For

appfirst video

Safeguard: A Partner for Growth
David Roth, CEO, AppFirst

safeguard video

Safeguard's 60 Years of Innovation
Stephen T. Zarrilli, CEO, Safeguard

thingworx video

The Value of Safeguard
Russ Fadel, CEO, ThingWorx

Our History of Innovation
Spans 6 Decades.

View Our History Timeline